Chris is an Australian-trained lawyer who has recently made the move to Thompsons Glasgow office where he is presently re-training in Scots Law.Scotland and Australia, tragically, are both historic world leaders in exposure to asbestos. The positive side is that both are also world leaders in justice for those with asbestos illnesses – but there is a lot the two countries could learn from each other.
A new report by the policy think tank ResPublica has shown that the UK Government is failing to take the risks posed by asbestos as seriously as other European Governments creating a “asbestos safety gap” with UK citizens paying the potential price.
The Health and Safety Executive (HSE) have this month issued a safety alert regarding the risk of exposure to harmful fumes from welding. This is in light of new scientific evidence from the International Agency for Research on Cancer that exposure to all welding fumes can cause lung cancer. It has also been indicated that there could be a link with kidney cancer.
It has been reported that two patients at the Queen Elizabeth University Hospital in Glasgow have recently died after contracting fungal infections caused by pigeon droppings. Both patients developed cryptococcosis, which is caused by fungus from soil or bird droppings.
On the 26th September 2018, the UN held a General Assembly on tuberculosis (TB) to discuss measures to end the spread of this disease. It is hoped that this meeting will lead to increased research into the condition, which, experts warn, may now be becoming drug-resistant. Following the meeting, the UK has already pledged increased funding towards development of new treatments.
A recent study has shown that people who have heavy exposure to certain types of metal are at increased risk of heart disease. The research team at the BMJ have confirmed this after reviewing studies of around 350,000 participants from around the world.
The NHS have recently agreed to fund a new drug which aims to treat severe asthma. The injection of Benralizumab, which costs almost £2,000 per dose, will be used for those suffering from eosinophilic asthma. Following approval for NHS by NICE (the National Institute for Health and Care Excellence) the drug will be given to patients as an injection once every four weeks for three months and once every eight weeks thereafter.